Wanbang Pharmaceutical announced that the company's stock trading price had a cumulative deviation value of more than 30% of the closing price increase for 3 consecutive trading days, which was an abnormal fluctuation. After self-inspection, there was no need to correct or supplement the company's early information. The operation was normal, there were no major changes in the internal and external environment, there were no undisclosed matters that should be disclosed, and the controlling shareholders and actual controllers did not trade stocks during this period. The company will disclose its semi-annual report on August 29 to remind investors to be aware of the risks.

Wanbang Pharmaceutical announced that the company's stock trading price had a cumulative deviation value of more than 30% of the closing price increase for 3 consecutive trading days, which was an abnormal fluctuation. After self-inspection, there was no need to correct or supplement the company's early information. The operation was normal, there were no major changes in the internal and external environment, there were no undisclosed matters that should be disclosed, and the controlling shareholders and actual controllers did not trade stocks during this period. The company will disclose its semi-annual report on August 29 to remind investors to be aware of the risks.